THURSDAY, Nov. 11, 2004 (HealthDayNews) -- A clinical trial to evaluate the impact of treating anemia on cardiovascular risks in people with type 2 diabetes and chronic kidney disease is being conducted by the biotechnology company Amgen Inc.
Details about the design of the trial were presented recently at the annual meeting of the American Society of Nephrology in St. Louis.
The trial will examine whether treating anemia with the drug Aransep lowers the risk of death and non-fatal cardiovascular events in people with chronic kidney disease (CKD) and type 2 diabetes. The international, multi-center study will include 4,000 patients.
"Current research suggests that anemia is an augmenter of cardiovascular risk in individuals with CKD and type 2 diabetes," lead investigator Dr. Mark Pfeffer, chief of medicine at Brigham and Women's Hospital and a professor at Harvard Medical School, said in a prepared statement.
Anemia is a common complication of CKD.
More information
The U.S. National Institute of Diabetes and Digestive and Kidney Diseases has more about kidney disease.
